Quantum Biopharma (QNTM) Income from Discontinued Operations (2019 - 2023)

Quantum Biopharma has disclosed Income from Discontinued Operations across 5 years of filings, most recently posting $3.1 million for Q4 2023.

• In Q4 2023, Income from Discontinued Operations changed N/A year-over-year to $3.1 million; the TTM figure through Sep 2023 stood at -$3.1 million (down 174.22% YoY), while the FY2022 annual figure was $3.1 million, up 329.83% from the prior year.
• Income from Discontinued Operations came in at $3.1 million for Q4 2023 at Quantum Biopharma, up from -$3.5 million in the prior quarter.
• In the past five years, Income from Discontinued Operations ranged from a high of $3.5 million in Q2 2022 to a low of -$3.5 million in Q2 2023.
• Average Income from Discontinued Operations over 5 years is -$240138.5, with a median of -$448721.5 recorded in 2021.
• Year-over-year, Income from Discontinued Operations jumped 881.86% in 2022 and tumbled 200.0% in 2023.
• Over 5 years, Income from Discontinued Operations stood at -$1.3 million in 2019, then surged by 68.48% to -$414124.0 in 2020, then surged by 317.26% to $899720.0 in 2021, then tumbled by 80.43% to $176104.0 in 2022, then jumped by 1658.53% to $3.1 million in 2023.
• Per Business Quant data, the three most recent Income from Discontinued Operations figures were $3.1 million in Q4 2023, -$3.5 million in Q2 2023, and $444506.0 in Q1 2023.